A strategy to control translation of mRNA vaccines reveals cell type–specific contributions to immunity that may be harnessed to enhance vaccine efficacy.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout

References
Marks, A. et al. Nat. Biotechnol. https://doi.org/10.1038/s41587-026-03099-z (2026).
Wang, J. et al. Nat. Biomed. Eng. 9, 201–214 (2025).
Rood, J. E. et al. Nat. Commun. 17, 1327 (2026).
Hassett, K. J. et al. Mol. Ther. Nucleic Acids 35, 102083 (2023).
Buckley, M. et al. Mol. Ther. 33, 1105–1117 (2025).
Zhu, Y. et al. Nat. Biomed. Eng. 8, 544–560 (2024).
Alameh, M. G. et al. Immunity 54, 2877–2892.e7 (2021).
Di, J. et al. Pharm. Res. 39, 105–114 (2022).
Tahtinen, S. et al. Nat. Immunol. 23, 532–542 (2022).
Parrett, B. J., Yamaoka, S. & Barry, M. A. Mol. Ther. Methods Clin. Dev. 33, 101402 (2024).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
H.M. and Y.H. declare no competing interests. D.G.A discloses competing interest due to past and present advising roles for Alnylam, Sanofi, Translate Bio, oRNA Therapeutics, CRISPR Therapeutics, Souffle Therapeutics and Combined Therapeutics.
Rights and permissions
About this article
Cite this article
Mughal, H., Hu, Y. & Anderson, D.G. Tuning the immune response to mRNA vaccines. Nat Biotechnol (2026). https://doi.org/10.1038/s41587-026-03125-0
Published:
Version of record:
DOI: https://doi.org/10.1038/s41587-026-03125-0